MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.480
+0.170
+7.36%
After Hours: 2.400 -0.08 -3.23% 19:18 05/27 EDT
OPEN
2.320
PREV CLOSE
2.310
HIGH
2.500
LOW
2.265
VOLUME
1.08M
TURNOVER
0
52 WEEK HIGH
6.50
52 WEEK LOW
1.930
MARKET CAP
368.85M
P/E (TTM)
-3.3356
1D
5D
1M
3M
1Y
5Y
Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today ...
GlobeNewswire · 2d ago
Pennsylvania Biotech Center's economic impact grows to $7B as it expands in Bucks County, report finds
The Pennsylvania Biotechnology Center of Bucks County and its affiliated organizations have generated an economic impact of $7.3 billion for the state during the past six years, according to a new study. The analysis, conducted by KLIOS Consulting economi...
American City Business Journals · 05/20 19:04
Arbutus to Present at H.C. Wainwright Global Investment Conference
WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today ...
GlobeNewswire · 05/17 11:30
Morning Brief: Top Financial Stories Dominating on Monday, May 9
CNBC Ford Motor Selling 8M Shares Of Rivian Automotive
Benzinga · 05/09 12:29
Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ
Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking royalties from the federal government.
Benzinga · 05/09 12:16
Arbutus Biopharma: Q1 Earnings Insights
  Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 05/05 13:32
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 12:55
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/05 12:43
More
No Data
Learn about the latest financial forecast of ABUS. Analyze the recent business situations of Arbutus Biopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
60.00%Buy
20.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ABUS stock price target is 6.70 with a high estimate of 10.00 and a low estimate of 4.000.
High10.00
Average6.70
Low4.000
Current 2.480
EPS
Actual
Estimate
-0.19-0.14-0.10-0.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 154
Institutional Holdings: 42.51M
% Owned: 28.58%
Shares Outstanding: 148.73M
TypeInstitutionsShares
Increased
38
6.37M
New
41
5.13M
Decreased
22
4.03M
Sold Out
19
2.46M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Frank Torti
President/Chief Executive Officer/Director
William Collier
Chief Financial Officer
David Hastings
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Elizabeth Howard
Chief Scientific Officer
Michael Sofia
Other
Michael McElhaugh
Other
Gaston Picchio
Independent Director
Daniel Burgess
Independent Director
Andrew Cheng
Independent Director
Richard Henriques
Independent Director
Keith Manchester
Independent Director
James Meyers
Independent Director
Tram Tran
Independent Director
Eric Venker
No Data
No Data
About ABUS
Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused primarily on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that have the potential to provide a curative regimen for chronic HBV infection. The Company has also initiated a drug discovery and development effort for treating coronaviruses, including COVID-19. The Company’s two lead product candidates are AB-729, its subcutaneously-delivered RNA interference (RNAi) product candidate that suppresses HBsAg expression, and AB-836, the Company’s next-generation oral capsid inhibitor that suppresses HBV DNA replication. AB-729 is in an ongoing Phase Ia/Ib clinical trial and a Phase IIa proof-of-concept clinical trial in collaboration with Assembly Biosciences, Inc.

Webull offers kinds of Arbutus Biopharma Corp stock information, including NASDAQ:ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.